GO:2001034 positive regulation of double-strand break repair via nonhomologous end joining: DNA Repair Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001034 describes any process that activates or increases the frequency, rate or extent of double-strand break repair via nonhomologous end joining (NHEJ).
• NHEJ is the dominant DSB repair pathway in mammalian cells and is regulated by acetylation, methylation, lactylation, and protein-protein interactions [2,6,8].
• Key positive regulators include Ku70/Ku80, DNA-PKcs, MRE11, DYNLL1, and Shieldin, whose dynamics determine repair outcome [2,3].
• Dysregulation of NHEJ positive regulation contributes to cancer chemoresistance, radiosensitivity, and antitumor immunity [2,5,6].
• TGFβ and NRF2 signaling intersect with NHEJ regulation, linking microenvironmental cues to DNA repair capacity [7,8].
• CRISPR-based models (KO, point mutation, knock-in, overexpression) are essential to dissect causal roles of NHEJ regulators [2,3].
Description
Double-strand breaks (DSBs) are the most cytotoxic DNA lesions, and their repair by nonhomologous end joining (NHEJ) is a major determinant of genome stability and therapy response [2,8]. The Gene Ontology term GO:2001034, positive regulation of double-strand break repair via nonhomologous end joining, captures the regulatory inputs that enhance this repair pathway. Understanding these positive regulators is critical because their activity influences cancer cell survival after radiation or chemotherapy, immune recognition, and normal tissue homeostasis [2,5,6]. Recent studies have identified post-translational modifications and protein complexes that directly stimulate NHEJ, including SMYD2-mediated Ku70 methylation, DYNLL1-MRE11 dynamics, and lactylation of LDH-A [2,3,6]. These findings position GO:2001034 as a central node for therapeutic targeting and biomarker discovery [4,7]. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of the term, its molecular players, disease relevance, and experimental strategies.
positive regulation of double-strand break repair via nonhomologous end joining At A Glance
| GO ID | GO:2001034 |
|---|---|
| GO term | positive regulation of double-strand break repair via nonhomologous end joining |
| Ontology | biological_process |
| Synonym | positive regulation of NHEJ |
| Major function | Enhances the frequency, rate or extent of NHEJ-mediated DSB repair |
| Regulatory inputs | Post-translational modifications (methylation, lactylation), protein-protein interactions, signaling pathways (TGFβ, NRF2) |
| Key effectors | Ku70/Ku80, DNA-PKcs, MRE11, DYNLL1, Shieldin, LDH-A |
| Disease relevance | Cancer chemoresistance, radiosensitivity, antitumor immunity, genome instability |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, Ribo-seq, proteomics, imaging |
What Is GO:2001034?
GO:2001034 is a biological process term defined as any process that activates or increases the frequency, rate or extent of double-strand break repair via nonhomologous end joining. In other words, it encompasses all molecular events that positively regulate the NHEJ machinery, from sensing DSBs to ligating broken ends, without altering the core definition of NHEJ itself [2,3].
Why Is positive regulation of double-strand break repair via nonhomologous end joining Important in Cell Biology?
GO:2001034 is important because positive regulation of NHEJ directly determines how cells survive genotoxic stress, and its dysregulation is linked to cancer therapy resistance and immune evasion [2,5,6]. Modulating this process can sensitize tumors to radiation or chemotherapy, and it also affects normal tissue responses to DNA damage [5,7].
• NHEJ is the primary DSB repair pathway in mammalian cells, and its positive regulation dictates repair efficiency.
• SMYD2 inhibition reduces Ku70 methylation, impairing NHEJ and enhancing antitumor immunity.
• DYNLL1-MRE11 complex dynamics control DNA end resection and Shieldin recruitment, influencing NHEJ choice.
• Lactylation of LDH-A promotes NHEJ and cisplatin resistance in lung adenocarcinoma.
• TGFβ signaling regulates DNA repair, including NHEJ, with implications for cancer progression.
• NRF2 modulates DNA damage repair pathways, including NHEJ, affecting chemoresistance.
• Transcriptional regulation of alternative end-joining can predict cancer treatment outcomes.
• HIF-1α/DNA-PKcs axis inhibition enhances radiosensitivity in non-small cell lung cancer.
• Targeting positive regulators of NHEJ offers therapeutic strategies for resistant tumors [2,5,6].
• CRISPR screens and bioinformatics are key to identifying novel NHEJ regulators.
What Happens During positive regulation of double-strand break repair via nonhomologous end joining?
DSB sensing and Ku70/Ku80 recruitment
In simple terms: The cell detects a break and loads a ring-shaped protein onto the DNA ends.
Upon DSB formation, the Ku70/Ku80 heterodimer rapidly binds DNA ends, serving as the initial sensor and recruitment platform for NHEJ factors. Positive regulation of this step can occur through post-translational modifications; for example, SMYD2-mediated methylation of Ku70 is required for efficient NHEJ, and its inhibition impairs repair and enhances antitumor immunity.
DNA-PKcs activation and end processing
In simple terms: A kinase called DNA-PKcs is activated to prepare the ends for ligation.
DNA-PKcs, a serine/threonine kinase, is recruited by Ku and activated at DSBs, where it coordinates end processing and ligation. Positive regulation of NHEJ includes signaling pathways that enhance DNA-PKcs activity; for instance, inhibition of the HIF-1α/DNA-PKcs axis radiosensitizes non-small cell lung cancer by suppressing DNA repair.
DYNLL1-MRE11 dynamics and end resection control
In simple terms: A protein complex controls how much DNA is trimmed back, which influences repair choice.
The DYNLL1-MRE11 complex regulates DNA end resection and the recruitment of Shieldin to DSBs, thereby influencing whether repair proceeds via NHEJ or homologous recombination. Positive regulation of NHEJ involves limiting excessive resection to favor direct ligation, and DYNLL1 plays a key role in this balance.
Ligation and post-translational regulation
In simple terms: The broken ends are sealed, and chemical tags on proteins can boost the process.
The final step of NHEJ involves ligation of processed ends by the XRCC4-LIG4 complex, which is positively regulated by various post-translational modifications [6,8]. Lactylation of lactate dehydrogenase A (LDH-A) enhances its activity and promotes NHEJ, contributing to cisplatin resistance in lung adenocarcinoma. Additionally, NRF2 signaling supports DNA damage repair, including NHEJ, under oxidative stress.
Signaling pathways that amplify NHEJ
In simple terms: External signals can tell the cell to ramp up its repair capacity.
TGFβ signaling regulates DNA repair pathways, including NHEJ, linking the tumor microenvironment to repair efficiency. Transcriptional programs downstream of TGFβ and other pathways can increase the expression of NHEJ core factors, thereby positively regulating the process [4,7]. These signaling inputs are being explored as predictive biomarkers for cancer treatment response.
Key Genes Involved in GO:2001034 positive regulation of double-strand break repair via nonhomologous end joining
The following genes and proteins are central to the positive regulation of NHEJ, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMYD2 | Methylates Ku70 to promote NHEJ | Inhibition impairs NHEJ and enhances antitumor immunity |
| XRCC6 (Ku70) | DSB sensor, forms Ku70/Ku80 heterodimer | Methylation status affects repair efficiency |
| XRCC5 (Ku80) | DSB sensor, forms Ku70/Ku80 heterodimer | Essential for NHEJ initiation |
| PRKDC (DNA-PKcs) | Kinase activated at DSBs, coordinates repair | Target for radiosensitization |
| MRE11 | End resection and repair choice | Complex with DYNLL1 regulates NHEJ vs HR |
| DYNLL1 | Regulates MRE11 and Shieldin recruitment | Controls end resection and NHEJ |
| SHLD1 | Shieldin complex, protects ends | Recruited by DYNLL1-MRE11 to promote NHEJ |
| SHLD2 | Shieldin complex, protects ends | Recruited by DYNLL1-MRE11 to promote NHEJ |
| LDHA | Lactylation enhances activity, promotes NHEJ | Linked to cisplatin resistance |
| TGFB1 | Signaling regulates DNA repair | Microenvironmental regulation of NHEJ |
| NRF2 (NFE2L2) | Transcription factor, supports DNA repair | Modulates NHEJ under oxidative stress |
| HIF1A | Regulates DNA-PKcs axis | Inhibition enhances radiosensitivity |
| LIG4 | DNA ligase IV, seals breaks | Core NHEJ ligation factor |
| XRCC4 | Ligase IV cofactor | Core NHEJ ligation factor |
| NHEJ1 (XLF) | Stimulates ligation | Core NHEJ factor |
| ATM | DNA damage response kinase | Upstream regulator of repair choice |
| TP53BP1 | Promotes NHEJ over HR | Key repair pathway selector |
How Is positive regulation of double-strand break repair via nonhomologous end joining Regulated?
Positive regulation of NHEJ is controlled by post-translational modifications, protein-protein interactions, and signaling pathways. SMYD2-mediated methylation of Ku70 is required for efficient NHEJ, and its inhibition impairs repair. DYNLL1-MRE11 complex dynamics regulate end resection and Shieldin recruitment, thereby influencing NHEJ. Lactylation of LDH-A enhances its activity and promotes NHEJ, contributing to chemoresistance. TGFβ and NRF2 signaling pathways also modulate DNA repair, including NHEJ, linking microenvironmental and oxidative stress cues to repair capacity [7,8].
positive regulation of double-strand break repair via nonhomologous end joining and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMYD2 | Cancer chemoresistance, antitumor immunity | KO and point mutation in cancer cell lines |
| PRKDC | Radioresistance in NSCLC | KO and overexpression in lung cancer cells |
| LDHA | Cisplatin resistance in lung adenocarcinoma | Knock-in of lactylation sites |
| MRE11 | Repair pathway choice, genome stability | Point mutation and tagged knock-in |
| NRF2 | Oxidative stress and chemoresistance | KO and overexpression |
Cancer chemoresistance and radiosensitivity
Positive regulation of NHEJ is a major mechanism of resistance to DNA-damaging therapies. SMYD2 inhibition impairs NHEJ and enhances antitumor immunity, suggesting a therapeutic strategy. In non-small cell lung cancer, inhibition of the HIF-1α/DNA-PKcs axis enhances radiosensitivity by suppressing DNA repair. Lactylation of LDH-A promotes NHEJ and cisplatin resistance in lung adenocarcinoma. Transcriptional regulation of alternative end-joining can predict cancer treatment outcomes.
Antitumor immunity
Defects in NHEJ can increase immunogenicity. SMYD2 inhibition-mediated hypomethylation of Ku70 impairs NHEJ repair and enhances antitumor immunity, linking DNA repair to immune surveillance.
Genome instability and oxidative stress
NRF2 modulates DNA damage repair, including NHEJ, under oxidative stress, and its dysregulation can contribute to genome instability. TGFβ signaling regulates DNA repair, with implications for cancer progression and tissue homeostasis.
From positive regulation of double-strand break repair via nonhomologous end joining-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SMYD2-mediated Ku70 methylation regulate NHEJ? | SMYD2 KO and Ku70 point mutation |
| How does DYNLL1-MRE11 complex control end resection? | DYNLL1 KO and tagged knock-in |
| Does LDH-A lactylation promote NHEJ? | LDHA knock-in of lactylation sites |
| Can HIF-1α/DNA-PKcs inhibition radiosensitize tumors? | PRKDC KO and HIF1A overexpression |
| What transcriptional programs regulate alternative end-joining? | Overexpression and reporter assays |
| How does NRF2 modulate NHEJ under oxidative stress? | NRF2 KO and overexpression |
How to Study the positive regulation of double-strand break repair via nonhomologous end joining Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR KO screen | Gene essentiality for NHEJ | Identify novel positive regulators [2,4] |
| Proteomics | Protein interactions and modifications | Map methylation/lactylation of repair factors [2,6] |
| Live-cell imaging | Repair protein recruitment kinetics | Study DYNLL1-MRE11 dynamics |
| RNA-seq | Transcriptional changes | Predict cancer treatment response |
| ChIP-seq | Transcription factor binding | Analyze TGFβ/NRF2 target genes [7,8] |
| Comet assay | DSB repair efficiency | Measure NHEJ capacity |
| Reporter assays | NHEJ activity | Screen for regulators |
| Bioinformatics | Pathway enrichment and signatures | Identify regulatory networks |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify positive regulators of NHEJ by selecting for cells that survive DSB-inducing agents [2,4]. These screens are powerful for discovering novel genes in the pathway.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can map methylation, lactylation, and phosphorylation events on NHEJ factors, revealing regulatory mechanisms [2,6].
Imaging and repair kinetics
Live-cell imaging of fluorescently tagged repair proteins (e.g., Ku70, MRE11) allows real-time monitoring of NHEJ dynamics and recruitment.
Transcriptional profiling and bioinformatics
RNA-seq and bioinformatic analyses of repair gene signatures can predict treatment response and identify regulatory networks [4,7].
How CRISPR Can Be Used to Study GO:2001034 positive regulation of double-strand break repair via nonhomologous end joining
Knockout
CRISPR knockout of positive regulators such as SMYD2, DYNLL1, or PRKDC can abolish NHEJ activity, sensitizing cells to DNA-damaging agents [2,3,5]. These models are essential to establish causality.
Point Mutation
Point mutations can be introduced to disrupt specific post-translational modification sites, such as Ku70 methylation or LDH-A lactylation, to dissect their role in NHEJ [2,6].
Knock-in
Knock-in of tagged versions of repair proteins (e.g., GFP-MRE11) allows real-time imaging and interaction studies. Knock-in of disease-associated variants can model repair defects.
Overexpression
Overexpression of NHEJ factors or signaling components (e.g., HIF-1α, NRF2) can enhance repair and confer resistance, providing models for therapeutic testing [5,8].
How EDITGENE Supports positive regulation of double-strand break repair via nonhomologous end joining Research
Researchers studying positive regulation of double-strand break repair via nonhomologous end joining-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with repair phenotypes. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of double-strand break repair via nonhomologous end joining research.
Frequently Asked Questions About positive regulation of double-strand break repair via nonhomologous end joining
What is GO:2001034?
GO:2001034 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of double-strand break repair via nonhomologous end joining.
What genes are involved in positive regulation of NHEJ?
Key genes include SMYD2, XRCC6 (Ku70), XRCC5 (Ku80), PRKDC (DNA-PKcs), MRE11, DYNLL1, SHLD1/2, LDHA, TGFB1, NRF2, and HIF1A [2,3,5,6,7,8].
How is NHEJ positively regulated?
Through post-translational modifications (methylation, lactylation), protein-protein interactions (DYNLL1-MRE11), and signaling pathways (TGFβ, NRF2, HIF-1α) [2,3,6,7,8].
Why is positive regulation of NHEJ important in cancer?
It contributes to chemoresistance and radioresistance; inhibiting positive regulators can sensitize tumors to therapy and enhance antitumor immunity [2,5,6].
What experimental models are used to study NHEJ regulation?
CRISPR knockout, point mutation, knock-in, overexpression cell models, and CRISPR screens are commonly used [2,3,4,5,6].
What is the role of SMYD2 in NHEJ?
SMYD2 methylates Ku70 to promote NHEJ; its inhibition impairs repair and enhances antitumor immunity.
How does DYNLL1 regulate NHEJ?
DYNLL1 forms a complex with MRE11 to control DNA end resection and Shieldin recruitment, influencing repair pathway choice.
Does lactylation affect NHEJ?
Yes, lactylation of LDH-A enhances its activity and promotes NHEJ, contributing to cisplatin resistance in lung adenocarcinoma.
How does TGFβ regulate NHEJ?
TGFβ signaling regulates DNA repair pathways, including NHEJ, linking the microenvironment to repair capacity.
What methods are used to measure NHEJ activity?
Comet assay, reporter assays, live-cell imaging, and CRISPR screens are used to measure NHEJ activity and identify regulators [3,4,5].
Conclusion
GO:2001034, positive regulation of double-strand break repair via nonhomologous end joining, is a critical biological process that governs genome stability and therapy response. The integration of post-translational modifications, protein complexes, and signaling pathways ensures tight control of NHEJ, and its dysregulation is implicated in cancer chemoresistance and immune evasion [2,5,6]. Continued research using CRISPR models and bioinformatics will uncover new therapeutic targets and biomarkers [4,7]. EDITGENE offers comprehensive services to support these investigations.
References
- 2. Tang M et al.. 2023. SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity.. Sci Adv 9(24):eade6624 PMID: 37315132
- 3. Swift ML et al.. 2023. Dynamics of the DYNLL1-MRE11 complex regulate DNA end resection and recruitment of Shieldin to DSBs.. Nat Struct Mol Biol 30(10):1456-1467 PMID: 37696958
- 4. Espín R et al.. 2025. Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.. NAR Cancer 7(1):zcaf007 PMID: 40061566
- 5. Li Y et al.. 2025. Guiqi Baizhu decoction enhances radiosensitivity in non-small cell lung cancer by inhibiting the HIF-1α/DNA-PKcs axis-mediated DNA repair.. Phytomedicine 140:156591 PMID: 40054178
- 6. Li J et al.. 2026. Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma.. Adv Sci (Weinh) 13(3):e10733 PMID: 41190808
- 7. Liu Q et al.. 2019. Misrepair in Context: TGFβ Regulation of DNA Repair.. Front Oncol 9:799 PMID: 31552165
- 8. Li J et al.. 2023. Roles of NRF2 in DNA damage repair.. Cell Oncol (Dordr) 46(6):1577-1593 PMID: 37365451
